Prestige Consumer Healthcare (PBH) Income towards Parent Company (2010 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Income towards Parent Company came in at $46.7 million in Q4 2025, down 23.49% year-on-year from $61.0 million in Q4 2024, and up 10.63% quarter-over-quarter from $42.2 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Income towards Parent Company (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Income towards Parent Company history runs 16 years deep, the most recent figure standing at $46.7 million for Q4 2025.
- On a quarterly basis, Income towards Parent Company fell 23.49% year-over-year to $46.7 million in Q4 2025; TTM through Dec 2025 was $186.5 million, a 12.82% decrease from a year earlier, with the FY2025 full-year figure at $214.6 million, up 2.52% from the prior year.
- Income towards Parent Company grew to $46.7 million in Q4 2025 per PBH's latest filing, from $42.2 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $61.0 million in Q4 2024 and bottomed at -$240.6 million in Q1 2023.
- The 5-year median for Income towards Parent Company is $50.6 million (2021), against an average of $35.9 million.
- Across the five-year window, Income towards Parent Company plunged 561.84% in 2023 and surged 120.56% in 2024, its largest moves.
- Year by year, Income towards Parent Company stood at $50.2 million in 2021, then increased by 3.46% to $52.0 million in 2022, then grew by 2.11% to $53.0 million in 2023, then grew by 15.05% to $61.0 million in 2024, then dropped by 23.49% to $46.7 million in 2025.
- Per Business Quant, the three latest PBH Income towards Parent Company figures stand at $46.7 million (Q4 2025), $42.2 million (Q3 2025), and $47.5 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.41 Bn | 2.35 Bn | 157.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.70 Mn |
| Sep 30, 2025 | 42.21 Mn |
| Jun 30, 2025 | 47.47 Mn |
| Mar 31, 2025 | 50.13 Mn |
| Dec 31, 2024 | 61.03 Mn |
| Sep 30, 2024 | 54.38 Mn |
| Jun 30, 2024 | 49.07 Mn |
| Mar 31, 2024 | 49.46 Mn |
| Dec 31, 2023 | 53.05 Mn |
| Sep 30, 2023 | 53.56 Mn |
| Jun 30, 2023 | 53.28 Mn |
| Mar 31, 2023 | -240.55 Mn |
| Dec 31, 2022 | 51.95 Mn |
| Sep 30, 2022 | 51.02 Mn |
| Jun 30, 2022 | 55.27 Mn |
| Mar 31, 2022 | 52.09 Mn |
| Dec 31, 2021 | 50.22 Mn |
| Sep 30, 2021 | 45.33 Mn |
| Jun 30, 2021 | 57.76 Mn |
| Mar 31, 2021 | 35.51 Mn |